JAK/STAT3 Represents a Therapeutic Target for Colorectal Cancer Patients with Stromal-Rich Tumors

Scientists investigated the use of JAK inhibitors for anti-cancer activity in coloretal cancer cell lines, mouse model organoids and patient-derived organoids.